Financhill
Sell
38

CRSP Quote, Financials, Valuation and Earnings

Last price:
$47.89
Seasonality move :
5.98%
Day range:
$47.34 - $51.47
52-week range:
$36.52 - $90.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.13x
Volume:
2.7M
Avg. volume:
2.5M
1-year change:
-41.86%
Market cap:
$4.1B
Revenue:
$35M
EPS (TTM):
-$4.37

Analysts' Opinion

  • Consensus Rating
    CRISPR Therapeutics AG has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 11 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $83.60, CRISPR Therapeutics AG has an estimated upside of 74.49% from its current price of $47.91.
  • Price Target Downside
    According to analysts, the lowest downside price target is $32.00 representing 33.21% downside risk from its current price of $47.91.

Fair Value

  • According to the consensus of 24 analysts, CRISPR Therapeutics AG has 74.49% upside to fair value with a price target of $83.60 per share.

CRSP vs. S&P 500

  • Over the past 5 trading days, CRISPR Therapeutics AG has overperformed the S&P 500 by 12.02% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • CRISPR Therapeutics AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • CRISPR Therapeutics AG revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CRISPR Therapeutics AG reported revenues of $35M.

Earnings Growth

  • CRISPR Therapeutics AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CRISPR Therapeutics AG reported earnings per share of -$0.44.
Enterprise value:
2.2B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-15.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$75.3M
Return On Assets:
-15.92%
Net Income Margin (TTM):
--
Return On Equity:
-18.65%
Return On Invested Capital:
-18.65%
Operating Margin:
-184.54%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $436K -- -- $200M $35M
Gross Profit -$109.8M $239.8M -$75.3M $180M $35M
Operating Income -$673.2M -$222.5M -$466.6M $69.6M -$64.6M
EBITDA -$649M -$202.7M -$447.3M $74.5M -$59.7M
Diluted EPS -$8.37 -$1.93 -$4.37 $1.13 -$0.44
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $1.7B $2.4B $1.9B $1.9B $1.9B
Total Assets $1.8B $2.8B $2.2B $2.2B $2.2B
Current Liabilities $94.3M $119.9M $121.1M $108.8M $87.8M
Total Liabilities $163.7M $352.4M $367.6M $346.8M $310M
Total Equity $1.7B $2.4B $1.9B $1.9B $1.9B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$495.7M -$260.4M -$142.8M -$96.1M -$50M
Cash From Investing -$258.7M $374.6M -$280.5M -$81.5M $105.8M
Cash From Financing $38.6M $62.7M $332M $38.9M $16.9M
Free Cash Flow -$532.9M -$272.3M -$144.7M -$96.8M -$50.3M
CRSP
Sector
Market Cap
$4.1B
$43.6M
Price % of 52-Week High
52.87%
47.61%
Dividend Yield
0%
0%
Shareholder Yield
-8.91%
-0.67%
1-Year Price Total Return
-41.86%
-34.6%
Beta (5-Year)
1.672
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $47.46
200-day SMA
Sell
Level $49.49
Bollinger Bands (100)
Buy
Level 41.39 - 49.87
Chaikin Money Flow
Sell
Level -41.3M
20-day SMA
Buy
Level $43.70
Relative Strength Index (RSI14)
Buy
Level 58.37
ADX Line
Buy
Level 26.59
Williams %R
Neutral
Level -45.2841
50-day SMA
Buy
Level $42.72
MACD (12, 26)
Buy
Level 2.05
25-day Aroon Oscillator
Buy
Level 20
On Balance Volume
Sell
Level -7.5M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (5.9986)
Buy
CA Score (Annual)
Level (0.2208)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.9072)
Sell
Piotroski F Score (Annual)
Level (3)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Stock Forecast FAQ

In the current month, CRSP has received 12 Buy ratings 11 Hold ratings, and 1 Sell ratings. The CRSP average analyst price target in the past 3 months is $83.60.

  • Where Will CRISPR Therapeutics AG Stock Be In 1 Year?

    According to analysts, the consensus estimate is that CRISPR Therapeutics AG share price will rise to $83.60 per share over the next 12 months.

  • What Do Analysts Say About CRISPR Therapeutics AG?

    Analysts are divided on their view about CRISPR Therapeutics AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CRISPR Therapeutics AG is a Sell and believe this share price will drop from its current level to $32.00.

  • What Is CRISPR Therapeutics AG's Price Target?

    The price target for CRISPR Therapeutics AG over the next 1-year time period is forecast to be $83.60 according to 24 Wall Street analysts, 12 of them rate the stock a Buy, 1 rates the stock a Sell, and 11 analysts rate the stock a Hold.

  • Is CRSP A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for CRISPR Therapeutics AG is a Buy. 12 of 24 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CRSP?

    You can purchase shares of CRISPR Therapeutics AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CRISPR Therapeutics AG shares.

  • What Is The CRISPR Therapeutics AG Share Price Today?

    CRISPR Therapeutics AG was last trading at $47.89 per share. This represents the most recent stock quote for CRISPR Therapeutics AG. Yesterday, CRISPR Therapeutics AG closed at $47.91 per share.

  • How To Buy CRISPR Therapeutics AG Stock Online?

    In order to purchase CRISPR Therapeutics AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock